58947-83-4

Basic information

• Product Name: (4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione
• Synonyms: (4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione;Antibiotic M-4365G3;Juvenimicin B1
• CAS NO: 58947-83-4
• Molecular Formula: C₃₁H₅₃NO₈
• Molecular Weight: 567.7544
• Mol File: 58947-83-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 729.2°Cat760mmHg
• Flash Point: 394.8°C
• Appearance: /
• Density: 1.13g/cm³
• Vapor Pressure: 1.5E-24mmHg at 25°C
• Refractive Index: 1.53
• PKA: 13.49±0.70(Predicted)
• CAS DataBase Reference: (4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione(58947-83-4)
• EPA Substance Registry System: (4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione(58947-83-4)

Safety Data

• Hazardous Substances Data: 58947-83-4(Hazardous Substances Data)

Usage

Description

(4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione is a complex organic compound that belongs to the class of fat-soluble vitamins, specifically vitamin A. It is characterized by its long molecular structure and is naturally found in various food sources, such as liver, eggs, and dairy products. (4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione is essential for maintaining proper vision, immune function, and reproductive health. Additionally, it is utilized in the skincare industry and as a supplement for its antioxidant properties and potential benefits to skin health. However, it is crucial to consume this compound in moderation to avoid toxicity and adverse health effects.

Uses

Used in Nutritional Supplements:
(4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione is used as a nutritional supplement for its role in maintaining vision, immune function, and reproduction. It is particularly important for individuals who may have a deficiency in vitamin A or those who wish to support their overall health.
Used in Skincare Products:
In the skincare industry, this compound is used as an ingredient for its antioxidant properties and potential benefits to skin health. It may help improve the appearance of the skin, promote a more youthful complexion, and protect against environmental stressors.
Used in Pharmaceutical Applications:
Due to its complex structure and biological activity, (4R,5S,6S,7R,9R,11E,15S,16R)-7-(2-Hydroxyethyl)-5,9,13,15-tetramethyl-16-ethyl-4-hydroxy-6-[3-(dimethylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyloxy]-1-oxacyclohexadeca-11,13-diene-2,10-dione may also be utilized in the development of pharmaceuticals, particularly for conditions related to vision, immune function, and reproductive health. Further research and development are necessary to fully understand its potential applications in this field.

InChI:InChI=1/C31H53NO8/c1-9-27-20(4)14-18(2)10-11-25(34)19(3)15-23(12-13-33)30(22(6)26(35)17-28(36)39-27)40-31-29(37)24(32(7)8)16-21(5)38-31/h10-11,14,19-24,26-27,29-31,33,35,37H,9,12-13,15-17H2,1-8H3/b11-10+,18-14+

Upstream product

• 56689-42-0 12,13-de-epoxy-12,13-didehydrorosaramicin 
• 1403991-96-7 (S)-4-benzyl-3-((4S,5R,E)-5-(tert-butyldimethylsilyloxy)-2,4-dimethylhept-2-enoyl)oxazolidin-2-one 
• 102518-92-3 (4S,5R,E)-5-(tert-butyldimethylsilyloxy)-2,4-dimethylhept-2-enal 
• 163457-34-9 (+)-(4S)-3-<(2'R)-2'-((benzyloxy)methyl)butanoyl>-4-benzyl-2-oxazolidinone 
• 219610-75-0 (S)-2-((benzyloxy)methyl)butan-1-ol 
• 16957-70-3 2-methylpent-2-enoic acid 
• 74758-60-4 protylonolide 
• 59227-83-7 12,13-de-epoxy-12,13-didehydro-20-deoxorosaramicin 
• 635758-46-2 (S)-3-((E)-2-methylpent-2-enoyl)-4-benzyloxazolidin-2-one 
• 1403991-98-9 (S)-3-((E,4S,5R)-5-hydroxyl-2,4-dimethylhept-2-enoyl)-4-benzyloxazolidin-2-one 

Downstream Products

• 56689-42-0 12,13-de-epoxy-12,13-didehydrorosaramicin 
• 35834-26-5 rosaramicin 
• 80240-61-5 5-O-desosaminyltylonolide 

Relevant articles and documents

Chemoenzymatic Total Synthesis and Structural Diversification of Tylactone-Based Macrolide Antibiotics through Late-Stage Polyketide Assembly, Tailoring, and C-H Functionalization

Polyketide synthases (PKSs) represent a powerful catalytic platform capable of effecting multiple carbon-carbon bond forming reactions and oxidation state adjustments. We explored the functionality of two terminal PKS modules that produce the 16-membered tylosin macrocycle, using them as biocatalysts in the chemoenzymatic synthesis of tylactone and its subsequent elaboration to complete the first total synthesis of the juvenimicin, M-4365, and rosamicin classes of macrolide antibiotics via late-stage diversification. Synthetic chemistry was employed to generate the tylactone hexaketide chain elongation intermediate that was accepted by the juvenimicin (Juv) ketosynthase of the penultimate JuvEIV PKS module. The hexaketide is processed through two complete modules (JuvEIV and JuvEV) in vitro, which catalyze elongation and functionalization of two ketide units followed by cyclization of the resulting octaketide into tylactone. After macrolactonization, a combination of in vivo glycosylation, selective in vitro cytochrome P450-mediated oxidation, and chemical oxidation was used to complete the scalable construction of a series of macrolide natural products in as few as 15 linear steps (21 total) with an overall yield of 4.6%.

Studies on juvenimicin, a new antibiotic. II. Isolation, chemical characterization and structures

-